Aethlon Medical
AEMD
13 hedge funds and large institutions have $89.2K invested in Aethlon Medical in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
86% more funds holding
Funds holding: 7 → 13 (+6)
2% more capital invested
Capital invested by funds: $87.3K → $89.2K (+$1.85K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.2K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$33.9K |
| 3 |
Jane Street
New York
|
+$26K |
| 4 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$13K |
| 5 |
HF
HRT Financial
New York
|
+$9.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$394 |
AEMD Hedge Fund Activity: Q2 2024 in Review
13 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q2 2024, worth a combined $89.2K — up 2.1% from $87.3K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AEMD positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $36.2K. The largest seller was Osaic Holdings, exiting entirely with an estimated $394 sold.
- 13 institutional investors held Aethlon Medical (AEMD) as of Q2 2024, up from 7 in Q1 2024.
- Funds reported $89.2K of Aethlon Medical stock for Q2 2024, up 2.1% quarter-over-quarter.
- 7 funds opened new Aethlon Medical positions in Q2 2024 and 1 closed out, a net change of +6 holders.
- The largest Aethlon Medical buyer in Q2 2024 was Susquehanna International Group, an estimated $36.2K added.
- The largest Aethlon Medical seller in Q2 2024 was Osaic Holdings, an estimated $394 sold.
Based on aggregated 13F filings for Q2 2024.